RT Journal Article SR Electronic T1 Dalbavancin is a novel antimicrobial against Gram-positive pathogens: clinical experience beyond labelled indications JF European Journal of Hospital Pharmacy JO Eur J Hosp Pharm FD British Medical Journal Publishing Group SP ejhpharm-2018-001711 DO 10.1136/ejhpharm-2018-001711 A1 María Núñez-Núñez, PharmD, MsC A1 Inmaculada Casas-Hidalgo A1 Ricardo García-Fumero A1 Inmaculada Vallejo-Rodríguez A1 Francisco Anguita-Santos A1 José Hernández-Quero A1 José Cabeza-Barrera A1 Andrés Ruiz-Sancho YR 2018 UL http://ejhp.bmj.com/content/early/2018/11/26/ejhpharm-2018-001711.abstract AB Very limited labelled indications have been approved for the newer antimicrobials. Data on the clinical uses, efficacy and safety of dalbavancin are scarce, thus here we sought to describe our clinical experience. 16-month observational prospective study was performed. 19 (86%) were used under off-label indications. 10 (46%) for osteoarticular infections, 5 (23%) bloodstream infections and 3 (14%) endocarditis. To highlight, one patient received dalbavancin as long-term suppressive therapy. Most frequent use reasons were promptly hospital discharge, 11 (65%), and the presence of resistant organisms involving limited treatment options, 5 (23%). Successful outcome was observed in >95% of the patients and only 1 (4.5%) adverse event was reported. Further evidence beyond labelled indications is urgently needed. Despite the limitations, dalbavancin appears to be a safe and efficient option for adult patients who have tried and/or failed other therapies due to multidrug-resistant Gram-positive organisms.